Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.

Enlivex Therapeutics Ltd.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NESS-ZIONA, ISRAEL, OCT. 28, 2025 (GLOBE NEWSWIRE) -- ENLIVEX THERAPEUTICS LTD. (NASDAQ: ENLV, THE COMPANY), A CLINICAL-STAGE MACROPHAGE REPROGRAMMING IMMUNOTHERAPY COMPANY, TODAY ANNOUNCED THAT IT WILL PRESENT A LATE-BREAKING POSTER ABSTRACT AT THE AMERICAN COLLEGE OF RHEUMATOLOGY (ACR) CONVERGENCE 2025, TAKING PLACE OCTOBER 2429 AT MCCORMICK PLACE CONVENTION CENTER IN CHICAGO, ILLINOIS.

ENLIVEX THERAPEUTICS TO PRESENT PHASE IIA 3-MONTH DATA OF ALLOCETRA IN PATIENTS WITH MODERATE-TO-SEVERE KNEE OSTEOARTHRITIS AT THE ACR CONVERGENCE 2025

NES-ZIONA, ISRAEL, SEPT. 29, 2025 (GLOBE NEWSWIRE) -- ENLIVEX THERAPEUTICS LTD. (NASDAQ: ENLV, THE COMPANY), A CLINICAL-STAGE MACROPHAGE REPROGRAMMING IMMUNOTHERAPY COMPANY, WILL PARTICIPATE IN A LIVE INVESTOR WEBINAR, ADVANCING INFLAMMATORY DISEASE TREATMENT: INSIGHTS & BREAKTHROUGHS FROM ENLIVEX'S KNEE OSTEOARTHRITIS PROGRAM, HOSTED BY D. BORAL CAPITAL ON SEPTEMBER 30, 2025, AT 10:00 AM EASTERN TIME. THE DISCUSSION WILL BRING TOGETHER LEADING KEY OPINION LEADERS (KOLS) IN MUSCULOSKELETAL DISEASE, ALONGSIDE ENLIVEX'S VICE CHAIRMAN AND D. BORAL'S RESEARCH DIRECTOR.THE SEPTEMBER 30 KOL WEBINAR WILL EXPLORE RECENT BREAKTHROUGHS IN TREATMENT APPROACHES DISCUSSING THE POSITIVE PHASE IIA TOPLINE DATA FROM ENLIVEX'S ALLOCETRA PROGRAM IN MODERATE-TO-SEVERE KNEE OSTEOARTHRITIS (KOA) PATIENTS. DATA DEMONSTRATED CLINICALLY MEANINGFUL AND HIGHLY STATISTICALLY SIGNIFICANT REDUCTION IN PAIN AND IMPROVEMENTS IN FUNCTION IN IDIOPATHIC, AGE-RELATED KNEE OSTEOARTHRITIS PATIENTS, A LARGE, UNDERSERVED POPULATION.

D. BORAL CAPITAL TO HOST KOL WEBINAR WITH WORLD LEADING EXPERTS FEATURING INSIGHTS & BREAKTHROUGHS FROM ENLIVEX'S KNEE OSTEOARTHRITIS PROGRAM

ALLOCETRA DEMONSTRATED STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENTS IN PAIN AND FUNCTION IN PHASE IIA TRIAL IN PRIMARY OSTEOARTHRITIS PATIENTS    SIX-MONTH DATA EXPECTED NOVEMBER 2025; PHASE IIB TRIAL INITIATION PLANNED FOR Q2 2026 NES-ZIONA, ISRAEL, SEPT. 11, 2025 (GLOBE NEWSWIRE) -- ENLIVEX THERAPEUTICS LTD.

ENLIVEX CEO ISSUES LETTER TO SHAREHOLDERS OUTLINING STRATEGIC ROADMAP FOLLOWING POSITIVE PHASE IIA ALLOCETRA RESULTS

NES-ZIONA, ISRAEL, SEPT. 09, 2025 (GLOBE NEWSWIRE) -- ENLIVEX THERAPEUTICS LTD.

ENLIVEX ANNOUNCES ISSUANCE OF NEW PATENT APPLICATION COVERING THE USE OF ALLOCETRA IN PATIENTS WITH OSTEOARTHRITIS

ENX-CL-05-001 TRIAL: 3-MONTHS TOPLINE DATA -IN THE OVERALL MODIFIED INTENTION-TO-TREAT (MITT) POPULATION, IMPROVEMENTS ACROSS ALL EFFICACY AND SECONDARY ENDPOINTS, INCLUDING 24% REDUCTION IN KNEE PAIN AND 26% IMPROVEMENT IN KNEE FUNCTION, WERE OBSERVED IN THE ALLOCETRATM TREATMENT ARM VS PLACEBO; MOREOVER, 72% REDUCTION IN KNEE PAIN AND 95% IMPROVEMENT IN KNEE FUNCTION WERE OBSERVED FOR AGE-RELATED PRIMARY OSTEOARTHRITIS PATIENTS COMPARED WITH PLACEBO  A SUBSTANTIAL, CLINICALLY MEANINGFUL AND STATISTICALLY SIGNIFICANT EFFECT IN COMMONLY USED PHASE III PRIMARY ENDPOINTS FOR KNEE OSTEOARTHRITIS CLINICAL TRIALS. -FAVORABLE SAFETY PROFILE  NO SEVERE ADVERSE EVENTS; LIMITED, TYPICALLY MILD TO MODERATE, TRANSIENT, AND TREATABLE SIDE EFFECTS OCCURRED IN MOST PATIENTS TREATED WITH ALLOCETRA -WEBINAR TODAY AT 8:00 A.M.

ENLIVEX ANNOUNCES POSITIVE TOPLINE DATA FROM MULTI-COUNTRY, RANDOMIZED, CONTROLLED, PHASE I/II TRIAL EVALUATING ALLOCETRA IN PATIENTS WITH MODERATE-TO-SEVERE KNEE OSTEOARTHRITIS

WEBINAR TO REVIEW RESULTS FROM MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING ALLOCETRA IN PATIENTS WITH MODERATE TO SEVERE KNEE OSTEOARTHRITIS NES-ZIONA, ISRAEL, AUG. 14, 2025 (GLOBE NEWSWIRE) -- ENLIVEX THERAPEUTICS LTD. (NASDAQ: ENLV, THE COMPANY), A CLINICAL-STAGE MACROPHAGE REPROGRAMMING IMMUNOTHERAPY COMPANY, TODAY ANNOUNCED IT WILL HOST AWEBINAR ON MONDAY, AUGUST 18, 2025, AT 8:00 AM EASTERN TIME TO PRESENT AND DISCUSS 3-MONTH TOPLINE RESULTS FROM THE PHASE IIA STAGE OF ITS PHASE I/IIA ENX-CL-05-001 TRIAL, A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED MULTI-CENTERED STUDY.

ENLIVEX TO PRESENT 3-MONTH TOPLINE DATA FROM PHASE IIA MODERATE/SEVERE KNEE OSTEOARTHRITIS TRIAL ON AUGUST 18 WEBINAR

NES-ZIONA, ISRAEL, JULY 28, 2025 (GLOBE NEWSWIRE) -- ENLIVEX THERAPEUTICS LTD. (NASDAQ: ENLV, THE COMPANY), A CLINICAL-STAGE MACROPHAGE REPROGRAMMING IMMUNOTHERAPY COMPANY, TODAY ANNOUNCED THAT ALL 134 PATIENTS IN ITS PHASE II STAGE OF ITS RANDOMIZED, CONTROLLED, BLINDED PHASE I/II TRIAL OF ALLOCETRA IN PATIENTS WITH MODERATE TO SEVERE KNEE OSTEOARTHRITIS, HAVE COMPLETED A FOLLOW-UP PERIOD OF AT LEAST THREE MONTHS, THE TRIAL'S PRIMARY TIMEPOINT FOR MEASUREMENT OF KEY ENDPOINTS. THE DATA ARE BEING ANALYZED AND AUDITED, WITH A TARGET DATE OF AUGUST 18, 2025 FOR THE PUBLIC RELEASE OF AUDITED TOPLINE RESULTS FOR THREE-MONTH KEY ENDPOINTS, INCLUDING SAFETY AND CHANGE FROM BASELINE IN KNEE PAIN AND FUNCTION.

ENLIVEX REAFFIRMS AUGUST 18, 2025 AS TARGET DATE FOR ANNOUNCEMENT OF PHASE II TOPLINE DATA

NESS-ZIONA, ISRAEL, JUNE 10, 2025 (GLOBE NEWSWIRE) -- ENLIVEX THERAPEUTICS LTD. (NASDAQ: ENLV, THE COMPANY), A CLINICAL-STAGE MACROPHAGE REPROGRAMMING IMMUNOTHERAPY COMPANY, TODAY ANNOUNCED THAT IT WILL PRESENT A POSTER AT THE EUROPEAN ALLIANCE OF ASSOCIATIONS FOR RHEUMATOLOGY (EULAR) EUROPEAN CONGRESS OF RHEUMATOLOGY, TAKING PLACE JUNE 11-14, 2025, IN BARCELONA, SPAIN.

ENLIVEX THERAPEUTICS TO PRESENT CLINICAL DATA OF ALLOCETRA IN OSTEOARTHRITIS AT EULAR 25 EUROPEAN CONGRESS OF RHEUMATOLOGY

PRESENTATION TO HIGHLIGHT ALLOCETRA AND THE THERAPEUTIC POTENTIAL OF MACROPHAGE REPROGRAMMING IN INFLAMMATORY DISEASES NESS-ZIONA, ISRAEL, MAY 20, 2025 (GLOBE NEWSWIRE) -- ENLIVEX THERAPEUTICS LTD. (NASDAQ: ENLV, THE COMPANY), A CLINICAL-STAGE MACROPHAGE REPROGRAMMING IMMUNOTHERAPY COMPANY, TODAY ANNOUNCED THAT THE COMPANY HAS BEEN SELECTED TO PRESENT AT THE UPCOMING ISRAELI BIOMED 2025 CONFERENCE, TAKING PLACE MAY 2123, 2025 IN TEL AVIV, ISRAEL.

ENLIVEX SELECTED TO PRESENT AT ISRAELI BIOMED 2025 CONFERENCE

PRESENTATIONS TO UNDERSCORE ALLOCETRATM'S NOVEL MECHANISM TARGETING IMMUNE IMBALANCE IN JOINT DISEASE NESS-ZIONA, ISRAEL, APRIL 23, 2025 (GLOBE NEWSWIRE) -- ENLIVEX THERAPEUTICS LTD. (NASDAQ: ENLV, THE COMPANY), A CLINICAL-STAGE MACROPHAGE REPROGRAMMING IMMUNOTHERAPY COMPANY, TODAY ANNOUNCED THAT IT WILL PRESENT TWO POSTER ABSTRACTS AT THE OSTEOARTHRITIS RESEARCH SOCIETY INTERNATIONAL (OARSI) 2025 WORLD CONGRESS ON OSTEOARTHRITIS, TAKING PLACE APRIL 24-27, 2025, IN INCHEON (SEOUL), SOUTH KOREA.

ENLIVEX THERAPEUTICS TO SHOWCASE ALLOCETRA'S POTENTIAL IN OSTEOARTHRITIS AT OARSI 2025 WORLD CONGRESS

NES-ZIONA, ISRAEL, APRIL 21, 2025 (GLOBE NEWSWIRE) -- ENLIVEX THERAPEUTICS LTD. (NASDAQ: ENLV, THE COMPANY), A CLINICAL-STAGE MACROPHAGE REPROGRAMMING IMMUNOTHERAPY COMPANY, TODAY ANNOUNCED THAT THE COMPANY COMPLETED ENROLLMENT OF ALL PATIENTS IN THE PHASE II STAGE OF ITS RANDOMIZED, CONTROLLED, BLINDED PHASE I/II TRIAL OF ALLOCETRA IN PATIENTS WITH MODERATE TO SEVERE KNEE OSTEOARTHRITIS. OVERALL, 133 PATIENTS WERE RANDOMIZED AND TREATED IN THE PHASE II STAGE.OREN HERSHKOVITZ, PH.D, CEO OF ENLIVEX, COMMENTED, WE ARE PLEASED TO HAVE COMPLETED THE RECRUITMENT OF PATIENTS IN THE PHASE II STAGE OF THIS TRIAL, WHICH FOLLOWS THE RECENTLY ANNOUNCED PROMISING INITIAL EFFICACY DATA FROM THE PHASE I STAGE. WE THEREFORE REITERATE OUR TIMELINE OBJECTIVE TO OBTAIN 3-MONTH TOPLINE DATA BY AUGUST 2025. WE BELIEVE ALLOCETRA HAS THE POTENTIAL TO TRANSFORM THE WAY OSTEOARTHRITIS PATIENTS ARE BEING TREATED TODAY, AND WE ARE EAGER TO RECEIVE THE TOPLINE DATA OF THE TRIAL.

ENLIVEX ANNOUNCES COMPLETION OF ENROLLMENT IN THE PHASE II STAGE OF ITS PHASE I/II TRIAL EVALUATING ALLOCETRA IN PATIENTS WITH MODERATE TO SEVERE KNEE OSTEOARTHRITIS

Enlivex Therapeutics Ltd.

ENLV

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Enlivex Therapeutics Ltd.

ENLV.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

ENLV